CA2578159A1 - Procedes et compositions destines a ameliorer la degradation de facteurs de transcription de recepteur nucleaire et utilisations correspondantes - Google Patents

Procedes et compositions destines a ameliorer la degradation de facteurs de transcription de recepteur nucleaire et utilisations correspondantes Download PDF

Info

Publication number: CA2578159A1
Authority: CA; Canada
Prior art keywords: receptor; nuclear receptor; degradation; nuclear; pathway
Prior art date: 2004-09-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002578159A

Other languages

English (en)

Inventor

Charles C.-Y. Shih

Ching-Yuan Su

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AndroScience Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-02

Filing date

2005-09-02

Publication date

2006-03-16

2005-01-27 Priority claimed from US11/045,181 external-priority patent/US20050209205A1/en

2005-09-02 Application filed by Individual filed Critical Individual

2006-03-16 Publication of CA2578159A1 publication Critical patent/CA2578159A1/fr

Status Abandoned legal-status Critical Current

Links

108020005497 Nuclear hormone receptor Proteins 0.000 title claims abstract description 153
108020004017 nuclear receptors Proteins 0.000 title claims abstract description 153
102000006255 nuclear receptors Human genes 0.000 title claims abstract description 152
230000015556 catabolic process Effects 0.000 title claims abstract description 98
238000006731 degradation reaction Methods 0.000 title claims abstract description 98
238000000034 method Methods 0.000 title claims abstract description 73
239000000203 mixture Substances 0.000 title claims abstract description 32
230000002708 enhancing effect Effects 0.000 title claims abstract description 31
102000040945 Transcription factor Human genes 0.000 title description 58
108091023040 Transcription factor Proteins 0.000 title description 58
230000037361 pathway Effects 0.000 claims abstract description 50
230000004913 activation Effects 0.000 claims abstract description 34
239000002537 cosmetic Substances 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims abstract description 11
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims abstract description 11
101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims abstract description 11
108010080146 androgen receptors Proteins 0.000 claims description 192
102100032187 Androgen receptor Human genes 0.000 claims description 189
210000004027 cell Anatomy 0.000 claims description 103
150000001875 compounds Chemical class 0.000 claims description 75
230000000694 effects Effects 0.000 claims description 52
238000011282 treatment Methods 0.000 claims description 45
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 27
206010060862 Prostate cancer Diseases 0.000 claims description 26
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 26
206010000496 acne Diseases 0.000 claims description 26
208000002874 Acne Vulgaris Diseases 0.000 claims description 25
208000027747 Kennedy disease Diseases 0.000 claims description 25
230000001939 inductive effect Effects 0.000 claims description 25
102000005969 steroid hormone receptors Human genes 0.000 claims description 25
108020003113 steroid hormone receptors Proteins 0.000 claims description 24
201000004384 Alopecia Diseases 0.000 claims description 23
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 23
206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 22
102000003998 progesterone receptors Human genes 0.000 claims description 21
108090000468 progesterone receptors Proteins 0.000 claims description 21
230000027455 binding Effects 0.000 claims description 16
230000003676 hair loss Effects 0.000 claims description 15
230000002401 inhibitory effect Effects 0.000 claims description 15
102000034527 Retinoid X Receptors Human genes 0.000 claims description 14
108010038912 Retinoid X Receptors Proteins 0.000 claims description 14
102000015694 estrogen receptors Human genes 0.000 claims description 14
108010038795 estrogen receptors Proteins 0.000 claims description 14
102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 13
108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 13
230000002452 interceptive effect Effects 0.000 claims description 13
108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 12
208000024891 symptom Diseases 0.000 claims description 11
238000006471 dimerization reaction Methods 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
208000026310 Breast neoplasm Diseases 0.000 claims description 7
230000026731 phosphorylation Effects 0.000 claims description 7
238000006366 phosphorylation reaction Methods 0.000 claims description 7
108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 6
206010052428 Wound Diseases 0.000 claims description 6
208000027418 Wounds and injury Diseases 0.000 claims description 6
206010005003 Bladder cancer Diseases 0.000 claims description 5
206010020112 Hirsutism Diseases 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 5
208000007466 Male Infertility Diseases 0.000 claims description 5
102000004265 STAT2 Transcription Factor Human genes 0.000 claims description 5
108010081691 STAT2 Transcription Factor Proteins 0.000 claims description 5
108010019992 STAT4 Transcription Factor Proteins 0.000 claims description 5
102000005886 STAT4 Transcription Factor Human genes 0.000 claims description 5
108010011005 STAT6 Transcription Factor Proteins 0.000 claims description 5
102000013968 STAT6 Transcription Factor Human genes 0.000 claims description 5
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
235000012754 curcumin Nutrition 0.000 claims description 5
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
201000007270 liver cancer Diseases 0.000 claims description 5
208000014018 liver neoplasm Diseases 0.000 claims description 5
208000017520 skin disease Diseases 0.000 claims description 5
201000005112 urinary bladder cancer Diseases 0.000 claims description 5
230000029663 wound healing Effects 0.000 claims description 5
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 4
229940109262 curcumin Drugs 0.000 claims description 4
239000004148 curcumin Substances 0.000 claims description 4
230000028993 immune response Effects 0.000 claims description 4
230000019491 signal transduction Effects 0.000 claims description 4
206010012438 Dermatitis atopic Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
210000004962 mammalian cell Anatomy 0.000 claims description 2
230000005937 nuclear translocation Effects 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
208000002254 stillbirth Diseases 0.000 claims description 2
231100000537 stillbirth Toxicity 0.000 claims description 2
102100033417 Glucocorticoid receptor Human genes 0.000 claims 2
239000002253 acid Substances 0.000 claims 2
210000005260 human cell Anatomy 0.000 claims 2
206010056340 Diabetic ulcer Diseases 0.000 claims 1
102000006381 STAT1 Transcription Factor Human genes 0.000 claims 1
102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
208000031271 Unwanted pregnancy Diseases 0.000 claims 1
239000003433 contraceptive agent Substances 0.000 claims 1
230000002254 contraceptive effect Effects 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
239000003098 androgen Substances 0.000 description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
201000010099 disease Diseases 0.000 description 25
108090000623 proteins and genes Proteins 0.000 description 25
230000000699 topical effect Effects 0.000 description 25
229960003604 testosterone Drugs 0.000 description 24
239000003981 vehicle Substances 0.000 description 24
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 22
238000012360 testing method Methods 0.000 description 22
241001465754 Metazoa Species 0.000 description 19
229960003473 androstanolone Drugs 0.000 description 19
239000002609 medium Substances 0.000 description 19
206010028980 Neoplasm Diseases 0.000 description 18
230000001965 increasing effect Effects 0.000 description 18
210000003491 skin Anatomy 0.000 description 17
239000000243 solution Substances 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000010261 cell growth Effects 0.000 description 16
230000007246 mechanism Effects 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
230000009467 reduction Effects 0.000 description 16
239000006071 cream Substances 0.000 description 15
235000018102 proteins Nutrition 0.000 description 15
210000004209 hair Anatomy 0.000 description 14
241000700159 Rattus Species 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
238000001262 western blot Methods 0.000 description 13
230000000762 glandular Effects 0.000 description 12
230000003993 interaction Effects 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
238000003556 assay Methods 0.000 description 11
239000012528 membrane Substances 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
102000003676 Glucocorticoid Receptors Human genes 0.000 description 10
-1 JC9 compound Chemical class 0.000 description 10
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 10
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 10
238000010171 animal model Methods 0.000 description 10
239000013592 cell lysate Substances 0.000 description 10
230000000670 limiting effect Effects 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
108010072866 Prostate-Specific Antigen Proteins 0.000 description 9
102000007066 Prostate-Specific Antigen Human genes 0.000 description 9
230000002280 anti-androgenic effect Effects 0.000 description 9
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 9
230000007423 decrease Effects 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
YPQLFJODEKMJEF-UHFFFAOYSA-N hydroxyflutamide Chemical compound CC(C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YPQLFJODEKMJEF-UHFFFAOYSA-N 0.000 description 9
210000001732 sebaceous gland Anatomy 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
239000000051 antiandrogen Substances 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 8
210000004940 nucleus Anatomy 0.000 description 8
229920000155 polyglutamine Polymers 0.000 description 8
108010040003 polyglutamine Proteins 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
102000007469 Actins Human genes 0.000 description 7
108010085238 Actins Proteins 0.000 description 7
239000000499 gel Substances 0.000 description 7
208000024963 hair loss Diseases 0.000 description 7
229940088597 hormone Drugs 0.000 description 7
239000005556 hormone Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000017854 proteolysis Effects 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
102000004388 Interleukin-4 Human genes 0.000 description 6
108090000978 Interleukin-4 Proteins 0.000 description 6
102000035195 Peptidases Human genes 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
239000004365 Protease Substances 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
210000000805 cytoplasm Anatomy 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
229940028885 interleukin-4 Drugs 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
230000006641 stabilisation Effects 0.000 description 6
238000011105 stabilization Methods 0.000 description 6
238000001890 transfection Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
108090000394 Erythropoietin Proteins 0.000 description 5
102000003951 Erythropoietin Human genes 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
108010065805 Interleukin-12 Proteins 0.000 description 5
102000013462 Interleukin-12 Human genes 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
108010057466 NF-kappa B Proteins 0.000 description 5
102000003945 NF-kappa B Human genes 0.000 description 5
108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 5
102100024819 Prolactin Human genes 0.000 description 5
108010057464 Prolactin Proteins 0.000 description 5
102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
102000001307 androgen receptors Human genes 0.000 description 5
229940105423 erythropoietin Drugs 0.000 description 5
239000005090 green fluorescent protein Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000011580 nude mouse model Methods 0.000 description 5
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
229940097325 prolactin Drugs 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000005945 translocation Effects 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
102100029951 Estrogen receptor beta Human genes 0.000 description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
108010051696 Growth Hormone Proteins 0.000 description 4
108010002386 Interleukin-3 Proteins 0.000 description 4
102000000646 Interleukin-3 Human genes 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 4
229940123573 Protein synthesis inhibitor Drugs 0.000 description 4
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 4
102100038803 Somatotropin Human genes 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
230000035508 accumulation Effects 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
230000032683 aging Effects 0.000 description 4
231100000360 alopecia Toxicity 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000000122 growth hormone Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000001739 intranuclear inclusion body Anatomy 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000007 protein synthesis inhibitor Substances 0.000 description 4
230000001850 reproductive effect Effects 0.000 description 4
230000011664 signaling Effects 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
101150029129 AR gene Proteins 0.000 description 3
208000019300 CLIPPERS Diseases 0.000 description 3
102000003952 Caspase 3 Human genes 0.000 description 3
108090000397 Caspase 3 Proteins 0.000 description 3
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 3
101150031823 HSP70 gene Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
102100040019 Interferon alpha-1/13 Human genes 0.000 description 3
108090000176 Interleukin-13 Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002586 Interleukin-7 Proteins 0.000 description 3
102000000704 Interleukin-7 Human genes 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
102000034570 NR1 subfamily Human genes 0.000 description 3
108020001305 NR1 subfamily Proteins 0.000 description 3
108010016731 PPAR gamma Proteins 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
108091027981 Response element Proteins 0.000 description 3
102000007078 STAT Transcription Factors Human genes 0.000 description 3
108010072819 STAT Transcription Factors Proteins 0.000 description 3
102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
206010068168 androgenetic alopecia Diseases 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 3
238000000326 densiometry Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
101150052825 dnaK gene Proteins 0.000 description 3
238000001378 electrochemiluminescence detection Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000001061 forehead Anatomy 0.000 description 3
210000003780 hair follicle Anatomy 0.000 description 3
230000003779 hair growth Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000001000 micrograph Methods 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
230000007170 pathology Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
208000023958 prostate neoplasm Diseases 0.000 description 3
230000030541 receptor transactivation Effects 0.000 description 3
229930002330 retinoic acid Natural products 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000035939 shock Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
102000003390 tumor necrosis factor Human genes 0.000 description 3
239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
241000867607 Chlorocebus sabaeus Species 0.000 description 2
244000163122 Curcuma domestica Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010041356 Estrogen Receptor beta Proteins 0.000 description 2
206010053759 Growth retardation Diseases 0.000 description 2
102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108090000177 Interleukin-11 Proteins 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
108010006519 Molecular Chaperones Proteins 0.000 description 2
102000005431 Molecular Chaperones Human genes 0.000 description 2
241000713333 Mouse mammary tumor virus Species 0.000 description 2
102000016979 Other receptors Human genes 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
102000000536 PPAR gamma Human genes 0.000 description 2
108010044210 PPAR-beta Proteins 0.000 description 2
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 2
108010066463 Retinoid X Receptor alpha Proteins 0.000 description 2
102000044159 Ubiquitin Human genes 0.000 description 2
108090000848 Ubiquitin Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
201000002996 androgenic alopecia Diseases 0.000 description 2
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000008504 concentrate Nutrition 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
235000003373 curcuma longa Nutrition 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
AIWVTQIFBWVBLQ-UHFFFAOYSA-N ethyl 7-(4-hydroxy-3-methoxyphenyl)-4-[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-5-oxohept-6-enoate Chemical compound C=1C=C(O)C(OC)=CC=1C=CC(=O)C(CCC(=O)OCC)C(=O)C=CC1=CC=C(O)C(OC)=C1 AIWVTQIFBWVBLQ-UHFFFAOYSA-N 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
238000013227 male C57BL/6J mice Methods 0.000 description 2
238000007726 management method Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
230000016273 neuron death Effects 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
108091008685 nuclear receptors type I Proteins 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
102000004164 orphan nuclear receptors Human genes 0.000 description 2
108090000629 orphan nuclear receptors Proteins 0.000 description 2
231100000255 pathogenic effect Toxicity 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
150000004492 retinoid derivatives Chemical group 0.000 description 2
238000000926 separation method Methods 0.000 description 2
206010040872 skin infection Diseases 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
230000004565 tumor cell growth Effects 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
102000009310 vitamin D receptors Human genes 0.000 description 2
108050000156 vitamin D receptors Proteins 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
ZMGUKFHHNQMKJI-CIOHCNBKSA-N (1e,4z,6e)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(\O)=C\C(=O)\C=C\C1=CC=C(OC)C(OC)=C1 ZMGUKFHHNQMKJI-CIOHCNBKSA-N 0.000 description 1
ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 1
XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 1
ZMGUKFHHNQMKJI-UHFFFAOYSA-N 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(O)=CC(=O)C=CC1=CC=C(OC)C(OC)=C1 ZMGUKFHHNQMKJI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
108091008716 AR-B Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
102000007371 Ataxin-3 Human genes 0.000 description 1
102000014461 Ataxins Human genes 0.000 description 1
108010078286 Ataxins Proteins 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
108030001720 Bontoxilysin Proteins 0.000 description 1
241000282817 Bovidae Species 0.000 description 1
208000013165 Bowen disease Diseases 0.000 description 1
208000019337 Bowen disease of the skin Diseases 0.000 description 1
208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
DCUROWAVXHWIAM-UHFFFAOYSA-N CCC(=O)C=C=C=C Chemical compound CCC(=O)C=C=C=C DCUROWAVXHWIAM-UHFFFAOYSA-N 0.000 description 1
101100534223 Caenorhabditis elegans src-1 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
206010008025 Cerebellar ataxia Diseases 0.000 description 1
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
235000003392 Curcuma domestica Nutrition 0.000 description 1
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
206010051651 Dermatitis papillaris capillitii Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
102100021238 Dynamin-2 Human genes 0.000 description 1
206010066042 Eczema vaccinatum Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010049119 Emotional distress Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
102100038595 Estrogen receptor Human genes 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010016936 Folliculitis Diseases 0.000 description 1
206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000035969 Genetic neuromuscular disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000025309 Hair disease Diseases 0.000 description 1
206010058898 Hand dermatitis Diseases 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 1
101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 1
101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 1
101100139918 Homo sapiens RARA gene Proteins 0.000 description 1
101000826376 Homo sapiens Signal transducer and activator of transcription 2 Proteins 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
208000007993 Kaposi Varicelliform Eruption Diseases 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000002569 Machado-Joseph Disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010068773 Mechanical urticaria Diseases 0.000 description 1
108010011756 Milk Proteins Proteins 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091093105 Nuclear DNA Proteins 0.000 description 1
102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
101150023417 PPARG gene Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
101150066717 Rara gene Proteins 0.000 description 1
208000021326 Ritter disease Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
102000014400 SH2 domains Human genes 0.000 description 1
108050003452 SH2 domains Proteins 0.000 description 1
101100285899 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSE2 gene Proteins 0.000 description 1
101710151387 Serine protease 1 Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
206010066409 Staphylococcal skin infection Diseases 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
206010061372 Streptococcal infection Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102100024547 Tensin-1 Human genes 0.000 description 1
108010088950 Tensins Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
102000000887 Transcription factor STAT Human genes 0.000 description 1
108050007918 Transcription factor STAT Proteins 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710119665 Trypsin-1 Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229940050528 albumin Drugs 0.000 description 1
229960001445 alitretinoin Drugs 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
229940090047 auto-injector Drugs 0.000 description 1
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940053031 botulinum toxin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000005773 cancer-related death Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000002038 chemiluminescence detection Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000008021 deposition Effects 0.000 description 1
201000000409 dermatographia Diseases 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960002311 dithranol Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
108010057988 ecdysone receptor Proteins 0.000 description 1
210000003204 ejaculatory duct Anatomy 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000002676 facial rejuvenation Methods 0.000 description 1
208000020157 familial dermatographia Diseases 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000010408 film Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
238000012632 fluorescent imaging Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
206010018797 guttate psoriasis Diseases 0.000 description 1
230000003659 hair regrowth Effects 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000005802 health problem Effects 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
102000046818 human AR Human genes 0.000 description 1
102000051840 human STAT2 Human genes 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
229940100994 interleukin-7 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
210000000754 myometrium Anatomy 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
230000004942 nuclear accumulation Effects 0.000 description 1
108091008581 nuclear androgen receptors Proteins 0.000 description 1
102000027507 nuclear receptors type II Human genes 0.000 description 1
108091008686 nuclear receptors type II Proteins 0.000 description 1
102000027495 nuclear receptors type III Human genes 0.000 description 1
108091008732 nuclear receptors type III Proteins 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
206010033898 parapsoriasis Diseases 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000011002 quantification Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000004508 retinoic acid derivatives Chemical class 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
230000037390 scarring Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000004378 sebocyte Anatomy 0.000 description 1
210000002374 sebum Anatomy 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940073490 sodium glutamate Drugs 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
206010048905 steatocystoma multiplex Diseases 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000037072 sun protection Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
235000013976 turmeric Nutrition 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

CA002578159A 2004-09-02 2005-09-02 Procedes et compositions destines a ameliorer la degradation de facteurs de transcription de recepteur nucleaire et utilisations correspondantes Abandoned CA2578159A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US60667804P	2004-09-02	2004-09-02
US60/606,678		2004-09-02
US11/045,181 US20050209205A1 (en)	2004-01-28	2005-01-27	Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US11/045,181		2005-01-27
PCT/US2005/031447 WO2006029040A2 (fr)	2004-09-02	2005-09-02	Procedes et compositions destines a ameliorer la degradation de facteurs de transcription de recepteur nucleaire et utilisations correspondantes

Publications (1)

Publication Number	Publication Date
CA2578159A1 true CA2578159A1 (fr)	2006-03-16

Family

ID=36036907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002578159A Abandoned CA2578159A1 (fr)	2004-09-02	2005-09-02	Procedes et compositions destines a ameliorer la degradation de facteurs de transcription de recepteur nucleaire et utilisations correspondantes

Country Status (6)

Country	Link
EP (1)	EP1804806A2 (fr)
JP (1)	JP2008540327A (fr)
AU (1)	AU2005282624A1 (fr)
CA (1)	CA2578159A1 (fr)
MX (1)	MX2007002583A (fr)
WO (1)	WO2006029040A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5292569B2 (ja) *	2006-11-10	2013-09-18	国立大学法人名古屋大学	抗老化転写因子活性化剤及びその利用
CN101711231B (zh)	2007-01-08	2014-03-12	安德鲁科技有限公司	具有(取代苯基)-丙烯醛部分的化合物、它们的衍生物、生物活性及其用途
US9000222B2 (en)	2007-01-08	2015-04-07	Androscience Corporation	Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en)	2007-01-08	2014-04-29	Androscience Corporation	Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
KR20100051808A (ko)	2007-07-31	2010-05-18	앤드로사이언스 코포레이션	안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2770842B1 (fr) *	1997-11-13	1999-12-17	Oreal	Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
US6790979B2 (en) *	2002-04-17	2004-09-14	University Of North Carolina At Chapel Hill	Curcumin analogues and uses thereof
CA2515589A1 (fr) *	2003-02-11	2004-08-26	Warner-Lambert Company Llc	Uree et derives de thio-uree

2005
- 2005-09-02 EP EP05806820A patent/EP1804806A2/fr not_active Withdrawn
- 2005-09-02 MX MX2007002583A patent/MX2007002583A/es not_active Application Discontinuation
- 2005-09-02 WO PCT/US2005/031447 patent/WO2006029040A2/fr not_active Ceased
- 2005-09-02 AU AU2005282624A patent/AU2005282624A1/en not_active Abandoned
- 2005-09-02 CA CA002578159A patent/CA2578159A1/fr not_active Abandoned
- 2005-09-02 JP JP2007530424A patent/JP2008540327A/ja active Pending

Also Published As

Publication number	Publication date
EP1804806A2 (fr)	2007-07-11
AU2005282624A1 (en)	2006-03-16
WO2006029040A3 (fr)	2008-12-04
JP2008540327A (ja)	2008-11-20
WO2006029040A2 (fr)	2006-03-16
MX2007002583A (es)	2007-09-14

Publication	Publication Date	Title
US20060084704A1 (en)	2006-04-20	Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US9446127B2 (en)	2016-09-20	Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
CA2481499C (fr)	2013-05-21	Utilisation de cyclopamine pour traiter le psoriasis et autres troubles cutanes
JP5424923B2 (ja)	2014-02-26	乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
Al-Mulla et al.	2011	Impaired TGF-β signaling and a defect in resolution of inflammation contribute to delayed wound healing in a female rat model of type 2 diabetes
DE69731302T2 (de)	2006-02-16	Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
Xu et al.	2021	Genistein suppresses allergic contact dermatitis through regulating the MAP2K2/ERK pathway
Tian et al.	2021	Pentacyclic triterpene compounds from loquat leaves reduce skin inflammation and epidermal hyperplasia in psoriasis via inhibiting the Th17 cells
He et al.	2024	Amygdalin ameliorates alopecia areata on C3H/HeJ mice by inhibiting inflammation through JAK2/STAT3 pathway
CA2578159A1 (fr)	2006-03-16	Procedes et compositions destines a ameliorer la degradation de facteurs de transcription de recepteur nucleaire et utilisations correspondantes
US20050209205A1 (en)	2005-09-22	Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
Guo et al.	2021	Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
Schoepe	2009	Investigations of in vitro Test Systems for the Detection of Glucocorticoid-induced Skin Atrophy as a Tool in Drug Discovery
HK1144552A (en)	2011-02-25	Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
HK1103630A (en)	2007-12-28	Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof

Legal Events

Date	Code	Title	Description
2011-09-02	FZDE	Dead